No. A generic of Ozempic has only a tentative approval, which means it cannot be sold. Generics on FDA's approved list: 8 of Victoza and 3 of Saxenda. Generic makers are lining up, though: 13 applications challenged Mounjaro's patents on a single day, May 13, 2026.
Read every day from FDA's Orange Book (FDA's file of Oct 9, 2026), Drugs@FDA and the Paragraph IV list (as of Oct 27, 2026). Newest event recorded here: Aug 28, 2026.
Brand by brand
Which brands have a generic, and what stands in the way
Patents and exclusivity already run out are left out. These dates are not launch dates: a court ruling or a settlement can bring a generic forward.
A generic maker can ask FDA for approval before a patent runs out by stating that the patent is invalid, unenforceable or not infringed. FDA calls this a paragraph IV certification. It is a filing, not an approval.
Brand
Strengths
First challenge
Applications that day
First generic approved
Last qualifying patent
Wegovy
25 mg
Aug 28, 2026
1
None yet
Feb 1, 2039
Zepbound
40 mg/2.4 mL and 50 mg/2.4 mL
Aug 26, 2026
1
None yet
Jul 22, 2039
Mounjaro
20 mg/2.4 mL and 30 mg/2.4 mL
Aug 24, 2026
1
None yet
Dec 30, 2041
Zepbound
20 mg/2.4 mL and 30 mg/2.4 mL
Aug 24, 2026
1
None yet
Jul 22, 2039
Mounjaro
10 mg/2.4 mL and 60 mg/2.4 mL
Jun 26, 2026
1
None yet
Dec 30, 2041
Zepbound
10 mg/2.4 mL and 60 mg/2.4 mL
Jun 26, 2026
1
None yet
Jul 22, 2039
Wegovy
7.2 mg/0.75 mL
Jun 22, 2026
1
None yet
Feb 17, 2041
Mounjaro
2.5 mg/0.5 mL 5 mg/0.5 mL
May 13, 2026
13
None yet
Dec 30, 2041
Mounjaro
7.5 mg/0.5 mL
May 13, 2026
13
None yet
Dec 30, 2041
Mounjaro
10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL
May 13, 2026
12
None yet
Dec 30, 2041
Zepbound
2.5 mg/0.5 mL 5 mg/0.5 mL
May 13, 2026
12
None yet
Jul 22, 2039
Zepbound
7.5 mg/0.5 mL
May 13, 2026
12
None yet
Jul 22, 2039
Zepbound
10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL
May 13, 2026
11
None yet
Jul 22, 2039
Zepbound
2.5 mg/0.5 mL 5 mg/0.5 mL
May 13, 2026
3
None yet
Jul 22, 2039
Mounjaro
2.5 mg/0.5 mL 5mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 15 mg/0.5 mL
May 13, 2026
2
None yet
Dec 30, 2041
Zepbound
7.5 mg/0.5 mL 10 mg/0.5 mL 15 mg/0.5 mL
May 13, 2026
2
None yet
Jul 22, 2039
Mounjaro
12.5 mg/0.5 mL
May 13, 2026
1
None yet
Dec 30, 2041
Zepbound
12.5 mg/0.5 mL
May 13, 2026
1
None yet
Jul 22, 2039
Wegovy
1.5 mg, 4 mg and 9 mg
Mar 11, 2026
1
None yet
Feb 1, 2039
Ozempic
1.5 mg, 4 mg and 9 mg
Dec 11, 2025
1
None yet
Feb 1, 2039
Rybelsus
3 mg, 7 mg and 14 mg
Jul 15, 2024
1
None yet
May 2, 2034
Ozempic
2 mg/3 mL
Apr 11, 2024
1
None yet
Jun 21, 2033
Ozempic
8 mg/3 mL
Dec 21, 2022
1
None yet
Feb 1, 2032
Wegovy
0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL
Oct 20, 2022
1
None yet
Feb 17, 2041
Ozempic
2 mg/1.5 mL and 4 mg/3 mL
Dec 6, 2021
7
None yet
Jun 21, 2033
Saxenda
18 mg/3 mL prefilled syringe
Aug 16, 2021
1
Aug 27, 2025
Jan 9, 2037
Victoza
18 mg/3 mL prefilled syringe
Dec 12, 2016
1
None yet
Sep 23, 2032
Byetta
250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe
Jun 11, 2014
1
None yet
Jan 14, 2020
6 of the brands without an approved generic have been challenged. A new chemical entity has five years of exclusivity, but a generic maker may file after four years if it challenges a patent. Ozempic's first challenge came on Dec 6, 2021, 7 applications on the first day they could. Mounjaro's first challenge came on May 13, 2026, 13 applications on the first day they could.
Why they rush: the first to file a complete challenge is generally eligible to sell the generic alone for 180 days. If the patent holder sues within 45 days, FDA approval is generally postponed for 30 months unless the patent expires or is judged invalid or not infringed first. All of this is as FDA describes it, which also says it decides on the applications themselves, not on this list.
What stands in the way
Each brand's patents and exclusivity
Every patent and exclusivity FDA lists for each brand and not yet run out. The maker declares its patents, and FDA says its role in listing them is ministerial, so a listing does not mean a court has upheld the patent.
Is there a generic Ozempic?
Not yet. FDA tentatively approved a generic of Ozempic from Apotex on Apr 7, 2026, and FDA says a product with a tentative approval is not an approved drug product, so it cannot be sold.
Exclusivity to Jan 28, 2028: To reduce the risk of sustained estimated glomerular filtration rate (EGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease (I-961)
Exclusivity to Oct 17, 2028: To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events (I-976)
23 listed patents, the last running to Feb 17, 2041
8129343, to Dec 5, 2031, covers the medicine itself, the product, a use
9278123, to Dec 16, 2031, covers the medicine itself, the product, a use
11382957, to Dec 16, 2031, covers the medicine itself, the product
Exclusivity to Mar 8, 2027: In combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (I-935)
Exclusivity to Aug 15, 2028: Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (nash), with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis) in adults (I-973)
Exclusivity to Dec 22, 2028: New product (NP)
Exclusivity to Mar 19, 2029: New strength (NS)
17 listed patents, the last running to Feb 17, 2041
8129343, to Dec 5, 2031, covers the medicine itself, the product
9278123, to Dec 16, 2031, covers the product, a use
Exclusivity to Oct 17, 2028: To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events (I-976)
16 listed patents, the last running to Feb 1, 2039
8129343, to Dec 5, 2031, covers the medicine itself, the product, a use
9278123, to Dec 16, 2031, covers the medicine itself, the product, a use
11382957, to Dec 16, 2031, covers the medicine itself, the product
Exclusivity codes and their wording are FDA's own.
Outside the United States
Generic semaglutide in Canada
Health Canada is the first G7 regulator to approve one. Checked Nov 6, 2026; it said in June 2026 that it was reviewing six more.
Apr 28, 2026: Dr. Reddy's Laboratories, a generic of Ozempic, for type 2 diabetes. Health Canada
May 1, 2026: Apotex, a generic of Ozempic, for type 2 diabetes. Health Canada
Jun 29, 2026: Apotex (Sevmia), a generic of Wegovy, for chronic weight management, age 12 and over. Health Canada
That does not make them legal to bring home. FDA says: “In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use”, and that it cannot ensure the safety of medicine bought from foreign sources. FDA on personal importation
FDA's Orange Book is plain about this: a product granted one “is not an approved drug product”. It is listed only once the approval becomes final.
Rating (AP1, AP2)
FDA's therapeutic equivalence code. The number appears when more than one reference product of the same strength is listed, which is how a Victoza generic and a Saxenda generic are told apart: both are 18 mg/3 mL liraglutide.
Patent
A property right granted by the US Patent and Trademark Office, generally for 20 years from filing. It can be issued or expire at any time, and it can cover the medicine, the product or a way of using it.
Not yet. FDA tentatively approved a generic of Ozempic from Apotex on Apr 7, 2026, and FDA says a product with a tentative approval is not an approved drug product, so it cannot be sold. Generic makers first challenged its patents on Dec 6, 2021, with 7 applications that day. Its FDA exclusivity runs to Oct 17, 2028. Its patent on the medicine itself runs to Dec 5, 2031, and its last listed patent to Feb 17, 2041. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Wegovy?
No. FDA has not approved a generic of Wegovy. Generic makers first challenged its patents on Oct 20, 2022. Its FDA exclusivity runs to Mar 19, 2029. Its patent on the medicine itself runs to Dec 5, 2031, and its last listed patent to Feb 17, 2041. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Rybelsus?
No. FDA has not approved a generic of Rybelsus. Generic makers first challenged its patents on Jul 15, 2024. Its FDA exclusivity runs to Oct 17, 2028. Its patent on the medicine itself runs to May 2, 2034, and its last listed patent to Feb 1, 2039. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Mounjaro?
No. FDA has not approved a generic of Mounjaro. Generic makers first challenged its patents on May 13, 2026, with 13 applications that day. Its FDA exclusivity runs to Dec 19, 2028. Its patent on the medicine itself runs to Jun 14, 2039, and its last listed patent to Dec 30, 2041. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Zepbound?
No. FDA has not approved a generic of Zepbound. Generic makers first challenged its patents on May 13, 2026, with 12 applications that day. Its FDA exclusivity runs to Dec 20, 2027. Its patent on the medicine itself runs to May 13, 2036, and its last listed patent to Jul 22, 2039. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Foundayo?
No. FDA has not approved a generic of Foundayo. Its FDA exclusivity runs to Apr 1, 2031. Its patent on the medicine itself runs to Sep 26, 2037. These dates are not a launch date: a court ruling or a settlement can bring one forward.
Is there a generic Victoza?
Yes. FDA has approved 8 generics of Victoza, the first from Hikma Pharmaceuticals USA on Dec 23, 2024.
Is there a generic Saxenda?
Yes. FDA has approved 3 generics of Saxenda, the first from Teva Pharmaceuticals Development on Aug 27, 2025.
Is there a generic Trulicity?
No. Trulicity is licensed as a biologic, so a copy would be a biosimilar, and FDA's record holds no application for one.
Is there a generic Byetta?
Not any more. FDA approved a generic of Byetta from Amneal EU on Nov 19, 2024, and it is now listed as discontinued. So is Byetta itself. Generic makers first challenged its patents on Jun 11, 2014.
When will generic Ozempic or Wegovy be available?
FDA does not publish a date, and neither of these dates is one. Ozempic's listed patent on semaglutide itself runs to Dec 5, 2031. A generic needs FDA's final approval, and patents can expire, be struck down in court or be licensed in a settlement, so a generic could come sooner or be held back by a later patent.
Is there a generic semaglutide in Canada?
Yes. Health Canada approved Dr. Reddy's Laboratories's on Apr 28, 2026, Apotex's on May 1, 2026, Apotex (Sevmia)'s on Jun 29, 2026. FDA says that in most circumstances it is illegal for individuals to import drugs into the US for personal use.
Is compounded semaglutide or tirzepatide a generic?
No. A generic is a copy FDA has approved and rated against the brand. A compounded medicine is mixed by a pharmacy and has no FDA approval, so FDA has not reviewed it for safety, effectiveness or quality.
Is generic liraglutide the same as Victoza or Saxenda?
FDA rates each of them therapeutically equivalent to one brand, shown by a code: AP1 for Victoza and AP2 for Saxenda. FDA says products with that rating can be expected to have the same clinical effect and safety profile. A generic carries its brand's label information, with certain exceptions FDA allows, so a Victoza generic is for what Victoza is for and a Saxenda generic for what Saxenda is for.
This page reports FDA's public records. It is not legal advice or a forecast of when any generic will reach the market.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.